Insulin portfolio
Grew 6 percent in Q2 2026 after a weak first half.
The numbers
What it is
Human and analogue insulins sold worldwide. This is a mature, high-volume business where pricing and volume matter more than new launches.
Why it matters to the stock. Insulin is a large, steady cash line. Its growth rate tells traders how the older diabetes business is holding up.
News
No stories tagged to this project yet.